Back

Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Antithrombotic pharmacotherapy Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Giang Son Arrighini

Bologna (Italy)

9 More presentations in this session

Presentation thumbnail
Discussant - Antithrombotic pharmacotherapy
Presentation thumbnail
Sex differences in dual antiplatelet therapy de-Escalation strategies in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Doctor G. Occhipinti (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Platelet reactivity of clopidogrel and aspirin with or without omeprazole in diabetes mellitus and coronary artery disease in thailand: a randomised double-blind placebo-controlled cross-over trial
Doctor M. Thungthienthong (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Thrombus perspectives: a comparative analysis of DOACs and warfarin
Doctor B. Resende (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Antithrombotic pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
What does the future hold for factor XIa vs. factor Xa inhibitors in atrial fibrillation, acute coronary syndrome and stroke?
thumbnail
Congress Session
Oral anticoagulation in atrial fibrillation: new insights
thumbnail
Congress Presentation
Balancing safety and efficacy: Factor XIa inhibitors vs. DOACs in atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources